Shire
The Power List 2018
Robert Dempsey
Group Vice President, Head of Global Ophthalmics Franchise Shire
How does Shire support leaders – both internal and external?
At Shire, we foster an environment where leaders are positive, accountable, results driven and great people managers. Through a fast-paced, entrepreneurial and international culture, we give people freedom and opportunity to excel while also setting a high bar for ethics and responsibility.
From an external perspective, we value feedback and insight from thought leaders within the eyecare community. We believe it is critical to engage and seek advice from the global leaders in ophthalmology as we have built out the franchise and expanded globally to address the millions of patients with eye diseases.
What does it take for a company like Shire to rise to a position of influence within eyecare?
Recognizing the potential of emerging scientific innovation to treat conditions of the eye, Shire made a strategic commitment to ophthalmology in 2013. Since then, growth in this highly specialized field has been driven by a combination of organic research, academic collaborations, acquisitions (e.g. SARcode Bioscience, Foresight Biotherapeutics), and a collaborative license agreement with Parion Sciences.
Shire brings unique and specialized disease expertise to treating conditions of the eye. Our commitment to providing potential therapies in ophthalmology stems from the same focus that drives our discovery, development and delivery of new treatments for each of our therapeutic areas: patient need.
How does Shire plan to continue leading the field – and making a difference to ophthalmologists and patients – in the coming years?
Despite the increasing demands we place on our eyes, very few companies or organizations take an interest in eye health. Shire recognized this vacuum of innovation in ophthalmology, and the need for innovation directed towards addressing some of the many unmet patient needs in this area. At the moment, we are particularly committed to dry eye disease, glaucoma and infectious conjunctivitis. We also have a strong desire to expand in the near term, from a research focus on the anterior segment to the posterior segment, as well as inherited retinal diseases. We are engaged across the entire ophthalmology community, and listen to patients and professionals as we evaluate more opportunities to advance eye health.
www.shire.com
Power List 2018
